The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog (Q36085774)

12 August 2017

1 reference

title

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog (English)

1 reference

12 August 2017

Hagop M Kantarjian

1 reference

12 August 2017

Stefan Faderl

1 reference

12 August 2017

Michael J Keating

1 reference

12 August 2017

William Plunkett

1 reference

12 August 2017

Sima Jeha

1 reference

12 August 2017

Varsha Gandhi

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

103

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

1985-1995

1 reference

Metabolism of 9-beta-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

The purine path to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Synthesis and biological activity of 2'-fluoro-2-halo derivatives of 9-.beta.-D-arabinofuranosyladenine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Liquid chromatographic study of acid stability of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine and related analogues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Metabolism and action of purine nucleoside analogs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Biochemical modulation of cytarabine triphosphate by clofarabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Acute myeloid leukemia in the older patient

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21005

7 January 2021

Identifiers

DOI

10.1002/CNCR.21005

1 reference

12 August 2017

1 reference